Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Neural Regulation01:37

Neural Regulation

45.1K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
45.1K
Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

2.6K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
2.6K
Excitatory and Inhibitory Effects of Neurotransmitters01:29

Excitatory and Inhibitory Effects of Neurotransmitters

15.2K
When an action potential reaches the presynaptic axon terminal, it releases neurotransmitters from the neuron into the synaptic cleft at a chemical synapse. The released neurotransmitter can be excitatory or inhibitory. The critical criteria commonly used to determine whether a molecule is a neurotransmitter at a chemical synapse are the molecule's presence in the presynaptic neuron. Second, its release is in response to strong presynaptic depolarization. And lastly, the presence of...
15.2K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

1.2K
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
1.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Social regression stems from a latent phase of GABAergic dysfunction and sensory breakdown in a model of synaptopathy.

Molecular psychiatry·2026
Same author

LRRK2 Mutation Alters Dopamine D2 Receptor Localization in Induced Pluripotent Stem Cells-Derived Astrocytes From Parkinson's Disease Patients: Implications for Neuronal Damage.

Journal of neurochemistry·2026
Same author

Mutations in the three synapsin genes lead to profound social deficits and cortical dysfunctions.

Progress in neuro-psychopharmacology & biological psychiatry·2026
Same author

An electrophysiological and proteomics roadmap for human induced glutamatergic neurons: fine-tuning of culture conditions for pathophysiological studies.

Cell death discovery·2026
Same author

Functional Blood-Brain Barrier Crossing by Biomimetic M13 Phage Vectors for Targeted Neuronal Delivery.

Advanced healthcare materials·2026
Same author

Phagocytosis by retinal pigment epithelium and microglia does not affect vision restoration by P3HT nanoparticles in Retinitis pigmentosa.

Cell death & disease·2026

Related Experiment Video

Updated: Apr 12, 2026

Recombinant α- β- and γ-Synucleins Stimulate Protein Phosphatase 2A Catalytic Subunit Activity in Cell Free Assays
09:36

Recombinant α- β- and γ-Synucleins Stimulate Protein Phosphatase 2A Catalytic Subunit Activity in Cell Free Assays

Published on: August 13, 2017

7.1K

α-synuclein and synapsin III cooperatively regulate synaptic function in dopamine neurons.

Michela Zaltieri1, Jessica Grigoletto1, Francesca Longhena1

  • 1Department of Molecular and Translational Medicine, University of Brescia, 25123, Brescia, Italy.

Journal of Cell Science
|May 14, 2015
PubMed
Summary

Alpha-synuclein (α-syn) interacts with and modulates synapsin III, a key protein in dopamine neuron function. This interaction impacts dopamine release and is altered in Parkinson's disease.

Keywords:
Dopamine releaseParkinson's diseaseSynapsin IIISynaptic vesiclesα-synuclein

More Related Videos

Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons
10:03

Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons

Published on: August 16, 2020

11.5K
A Method to Study α-Synuclein Toxicity and Aggregation Using a Humanized Yeast Model
08:24

A Method to Study α-Synuclein Toxicity and Aggregation Using a Humanized Yeast Model

Published on: November 25, 2022

2.8K

Related Experiment Videos

Last Updated: Apr 12, 2026

Recombinant α- β- and γ-Synucleins Stimulate Protein Phosphatase 2A Catalytic Subunit Activity in Cell Free Assays
09:36

Recombinant α- β- and γ-Synucleins Stimulate Protein Phosphatase 2A Catalytic Subunit Activity in Cell Free Assays

Published on: August 13, 2017

7.1K
Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons
10:03

Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons

Published on: August 16, 2020

11.5K
A Method to Study α-Synuclein Toxicity and Aggregation Using a Humanized Yeast Model
08:24

A Method to Study α-Synuclein Toxicity and Aggregation Using a Humanized Yeast Model

Published on: November 25, 2022

2.8K

Area of Science:

  • Neuroscience
  • Molecular Biology
  • Pathology

Background:

  • Parkinson's disease (PD) is characterized by dopaminergic neuron loss and Lewy bodies, primarily composed of alpha-synuclein (α-syn).
  • Synapsin III (SYN3) is crucial for regulating synaptic function in dopamine neurons.

Purpose of the Study:

  • To investigate the interaction between α-syn and synapsin III.
  • To elucidate the role of this interaction in dopamine neuron function and Parkinson's disease.

Main Methods:

  • Utilized α-syn-null mice models.
  • Analyzed synapsin III expression, localization, and synaptic vesicle organization.
  • Measured dopamine release and locomotor responses.

Main Results:

  • Absence of α-syn leads to increased and redistributed synapsin III, altering synaptic vesicle pools.
  • α-syn-null mice exhibit altered dopamine overflow and release dynamics.
  • Synapsin III accumulation observed in the caudate and putamen of Parkinson's disease patients.

Conclusions:

  • α-syn and synapsin III engage in a reciprocal modulatory relationship.
  • This interaction is vital for regulating dopamine neuron synaptic function.
  • Dysregulation of synapsin III is implicated in Parkinson's disease pathogenesis.